Literature DB >> 11458971

Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature.

J Muench1, M Carey.   

Abstract

BACKGROUND: Since the introduction of atypical antipsychotic medications, beginning with clozapine in 1990, several case reports in the psychiatric literature have suggested that they might be associated with new onset of diabetes mellitus as well as with diabetic ketoacidosis.
METHODS: We report the case of a 38-year-old patient with schizophrenia who suddenly developed diabetes mellitus and ketoacidosis 12 months after starting olanzapine. Similar cases in the literature were found through a MEDLINE-assisted search using the key words "schizophrenia," "diabetes mellitus," "ketoacidosis," and "adverse drug reaction."
RESULTS: Including this case, 30 patients have been reported in the literature to have developed diabetes or have lost diabetic control after starting clozapine, olanzapine, or quetiapine. Twelve of these 30 developed diabetic ketoacidosis. Two limited quantitative studies have added evidence toward this association.
CONCLUSION: Although a causal relation has not been definitively proved, the number of cases reported in the literature suggests there might be an association between atypical antipsychotic medications and diabetes mellitus. Primary care physicians who care for patients with schizophrenia should be aware of this possible association.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11458971

Source DB:  PubMed          Journal:  J Am Board Fam Pract        ISSN: 0893-8652


  9 in total

Review 1.  Atypical antipsychotics and diabetic ketoacidosis: a review.

Authors:  Melanie D Guenette; Margaret Hahn; Tony A Cohn; Celine Teo; Gary J Remington
Journal:  Psychopharmacology (Berl)       Date:  2013-01-24       Impact factor: 4.530

Review 2.  Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors:  John W Newcomer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications.

Authors:  Kristina Melkersson; Marja-Liisa Dahl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine.

Authors:  Krishnan Ramaswamy; Chris M Kozma; Henry Nasrallah
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

5.  Quetiapine-induced Diabetic Ketoacidosis.

Authors:  Soumitra Das; Dhanya S Palappallil; Arjun Kartha; Varun Rajan
Journal:  Indian J Psychol Med       Date:  2018 Jan-Feb

Review 6.  Treatment of Diabetic Ketoacidosis Associated With Antipsychotic Medication: Literature Review.

Authors:  Antonia Vuk; Maja Baretic; Martina Matovinovic Osvatic; Igor Filipcic; Nikolina Jovanovic; Martina Rojnic Kuzman
Journal:  J Clin Psychopharmacol       Date:  2017-10       Impact factor: 3.153

7.  Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.

Authors:  Jennifer Kern Sliwa; Cynthia A Bossie; Dong-Jing Fu; Ibrahim Turkoz; Larry Alphs
Journal:  Neuropsychiatr Dis Treat       Date:  2012-08-27       Impact factor: 2.570

8.  Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial.

Authors:  Cynthia A Bossie; Dong-Jing Fu; Jennifer Kern Sliwa; Yi-Wen Ma; Larry Alphs
Journal:  Ther Adv Psychopharmacol       Date:  2011-08

9.  A case report and literature review of olanzapine-associated hyperglycemia with previous history of gestational diabetes.

Authors:  Jennifer N Alastanos; Devika Suri; Hayato DeLellis; Andrea Mapugay
Journal:  Ment Health Clin       Date:  2022-01-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.